Literature DB >> 30639036

Lentiviral Gene Therapy in HSCs Restores Lineage-Specific Foxp3 Expression and Suppresses Autoimmunity in a Mouse Model of IPEX Syndrome.

Katelyn E Masiuk1, Jennifer Laborada1, Maria Grazia Roncarolo2, Roger P Hollis1, Donald B Kohn3.   

Abstract

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a devastating autoimmune disease caused by mutations in FoxP3, a transcription factor required for the development and function of regulatory T cells (Treg cells). Allogeneic hematopoietic stem cell transplant (HSCT) can be curative, but suitable donors are often unavailable. Here, we demonstrate a strategy for autologous HSCT and gene therapy utilizing a lentiviral vector (LV) to restore FoxP3 expression under the control of endogenous human FOXP3 regulatory elements. Both murine transplant models and humanized mice engrafted with LV-modified HSCs show high levels of LV expression selective for CD4+CD25+FoxP3+ Treg cells. LV transduction of scurfy (FoxP3mut) HSCs restores development of functional FoxP3+ Treg cells that suppress T cell proliferation in vitro and rescue the scurfy autoimmune phenotype in vivo. These findings demonstrate preclinical efficacy for the treatment of IPEX patients by autologous HSC transplant and may provide valuable insights into new cell therapies for autoimmunity.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FoxP3; IPEX; Tregs; autoimmunity; gene therapy; hematopoietic stem cells

Mesh:

Substances:

Year:  2019        PMID: 30639036     DOI: 10.1016/j.stem.2018.12.003

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  15 in total

1.  T-lymphoid progenitor-based immunotherapies: clinical perspectives for one and all.

Authors:  P Gaudeaux; R D Moirangthem; J Paillet; M Martin-Corredera; H Sadek; P Rault; A Joshi; J Zuber; T S Soheili; O Negre; I André
Journal:  Cell Mol Immunol       Date:  2022-09-30       Impact factor: 22.096

2.  A combination of cyclophosphamide and interleukin-2 allows CD4+ T cells converted to Tregs to control scurfy syndrome.

Authors:  Marianne Delville; Florence Bellier; Juliette Leon; Roman Klifa; Sabrina Lizot; Hélène Vinçon; Steicy Sobrino; Romane Thouenon; Armance Marchal; Alexandrine Garrigue; Juliette Olivré; Soëli Charbonnier; Chantal Lagresle-Peyrou; Mario Amendola; Axel Schambach; David Gross; Baptiste Lamarthée; Christophe Benoist; Julien Zuber; Isabelle André; Marina Cavazzana; Emmanuelle Six
Journal:  Blood       Date:  2021-04-29       Impact factor: 22.113

Review 3.  Genetic engineering of T cells for immunotherapy.

Authors:  Gavin I Ellis; Neil C Sheppard; James L Riley
Journal:  Nat Rev Genet       Date:  2021-02-18       Impact factor: 59.581

4.  In situ conversion of defective Treg into SuperTreg cells to treat advanced IPEX-like disorders in mice.

Authors:  Yongqin Li; Yuxin Chen; Shaoshuai Mao; Ravinder Kaundal; Zhengyu Jing; Qin Chen; Xinxin Wang; Jing Xia; Dahai Liu; Jianlong Sun; Haopeng Wang; Tian Chi
Journal:  Nat Commun       Date:  2020-06-03       Impact factor: 14.919

5.  CRISPR-based gene editing enables FOXP3 gene repair in IPEX patient cells.

Authors:  M Goodwin; E Lee; U Lakshmanan; S Shipp; L Froessl; F Barzaghi; L Passerini; M Narula; A Sheikali; C M Lee; G Bao; C S Bauer; H K Miller; M Garcia-Lloret; M J Butte; A Bertaina; A Shah; M Pavel-Dinu; A Hendel; M Porteus; M G Roncarolo; R Bacchetta
Journal:  Sci Adv       Date:  2020-05-06       Impact factor: 14.136

Review 6.  Gene Therapy for Primary Immunodeficiency.

Authors:  Benjamin C Houghton; Claire Booth
Journal:  Hemasphere       Date:  2020-12-29

Review 7.  Gene Therapies for Primary Immune Deficiencies.

Authors:  Lisa A Kohn; Donald B Kohn
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

Review 8.  Hematopoietic Stem Cells in Type 1 Diabetes.

Authors:  Ida Pastore; Emma Assi; Moufida Ben Nasr; Andrea Mario Bolla; Anna Maestroni; Vera Usuelli; Cristian Loretelli; Andy Joe Seelam; Ahmed Abdelsalam; Gian Vincenzo Zuccotti; Francesca D'Addio; Paolo Fiorina
Journal:  Front Immunol       Date:  2021-07-09       Impact factor: 7.561

9.  Gene therapy for severe combined immunodeficiencies and beyond.

Authors:  Alain Fischer; Salima Hacein-Bey-Abina
Journal:  J Exp Med       Date:  2020-01-06       Impact factor: 14.307

10.  NHC-gold compounds mediate immune suppression through induction of AHR-TGFβ1 signalling in vitro and in scurfy mice.

Authors:  Xinlai Cheng; Stefanie Haeberle; Iart Luca Shytaj; Rodrigo A Gama-Brambila; Jannick Theobald; Shahrouz Ghafoory; Jessica Wölker; Uttara Basu; Claudia Schmidt; Annika Timm; Katerina Taškova; Andrea S Bauer; Jörg Hoheisel; Nikolaos Tsopoulidis; Oliver T Fackler; Andrea Savarino; Miguel A Andrade-Navarro; Ingo Ott; Marina Lusic; Eva N Hadaschik; Stefan Wölfl
Journal:  Commun Biol       Date:  2020-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.